Active, Not Recruiting
A Study of BMS-986148 in Patients With Select Advanced Solid Tumors - CA008-002
Updated: 8 June, 2020 | ClinicalTrials.gov
Print Friendly Summary
Trial Details
Phase
Gender(s)
Age Range
Active, Not Recruiting
Treatment Options
For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com Inclusion Criteria: - Must have pancreatic, ovarian, gastric, non-small cell cancer or mesothelioma. For dose expansion, must have tumor that is positive for mesothelin - Expected to have life expectancy of at least 3 months - Men and women 18 years old or older (or local age of majority) - Must have measurable tumor per Response Evaluation Criteria In Solid Tumors (RECIST) or modified RECIST for malignant pleural mesothelioma - ECOG of 0 to 1 Exclusion Criteria: - Cancer metastases in the brain - Moderate eye disorders - Active infection or past hepatitis B or C infection - Major surgery less than 1 month before the start of the study - Uncontrolled heart disease - Impaired liver or bone marrow function - History of allergy to mesothelin-directed antibodies, tubulysin, monoclonal antibodies, nivolumab or related compounds
We strongly recommend you contact BMS to report Side Effects (Adverse Events)
Side Effects (Adverse Events) and other reportable events are defined here
Report Side Effects (Adverse Events) or Product Quality Complaints: Medical Information
